Teva, Alpharma in Deal on Generic Neurontin
From Reuters
Generic drug makers Teva Pharmaceutical Industries Ltd. and Alpharma Inc. said they agreed to share revenue from generic versions of Pfizer Inc.’s top-selling epilepsy drug, Neurontin.
Alpharma would have a six-month U.S. generic exclusivity period for copycat capsules and perhaps for copycat tablets if generic drug makers win their court battles with Pfizer.
Shares of Alpharma jumped $3.10 to $24 on the NYSE, while shares of Teva rose 40 cents to $66.17 on Nasdaq.
From Reuters
